Lung Cancer

Latest News


CME Content


Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims to improve the drug development process while exploring therapeutic options for this challenging malignancy.

The results of two phase III trials reported at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer have found that enobosarm, a first-in-class, nonsteroidal, oral selective androgen receptor modulator (SARM), led to an increase in lean body mass (LBM) compared with a decline in LBM observed with placebo for patients with non-small cell lung cancer (NSCLC).

Leading experts in the rapidly evolving field of lung cancer treatment assembled for the 1st Annual Miami Lung Cancer Conferenceâ„¢ in Miami Beach, Florida, on March 8, to offer their perspectives on the latest research and provide clinical insights for practitioners dealing with challenging cases.

The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.

The Caring Ambassadors Program

By

CAP is a nonprofit providing information, resource referrals for personal support, and public advocacy for people at risk for or living with lung cancer or hepatitis C.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.